Colchicine in High-risk Patients With Acute Non-disabling Cerebrovascular Events (CHANCE-3)
Status:
Not yet recruiting
Trial end date:
2025-01-31
Target enrollment:
Participant gender:
Summary
This study is a multicentre, randomized, double-blind, placebo-controlled,
investigator-sponsored study that aims to investigate the efficacy of colchicine in
preventing recurrent stroke in the patients with high-risk non-disabling cerebrovascular
events and a hsCRP level of ≥2mg/L.